Skip to main contentSkip to navigationSkip to navigation
Molnupiravir pills
Molnupiravir treatment pills. Ministers and health officials said the deals could play a significant role in reducing the extent of serious Covid cases over the winter. Photograph: Merck & Co Inc/Reuters
Molnupiravir treatment pills. Ministers and health officials said the deals could play a significant role in reducing the extent of serious Covid cases over the winter. Photograph: Merck & Co Inc/Reuters

No 10 to buy new antiviral treatments for Covid in time for winter

This article is more than 2 years old

Trials show one of drugs cuts risk of hospitalisation or death for patients by half

No 10 has made deals to buy hundreds of thousands of doses of two new antiviral treatments for coronavirus, ministers have announced, at least one of which it is hoped will be approved for use in the UK ahead of the winter.

One deal covers 480,000 courses of molnupiravir, which can be taken as a pill twice a day. In trials, the drug, made by Merck, known as MSD outside the US, has been shown to cut the risk of hospitalisation or death for patients not in hospital by half.

The other treatment is PF-07321332/ritonavir, a combination of another oral antiviral treatment with ritonavir, a drug usually used to treat HIV/Aids. Made by Pfizer, the UK has a deal for 250,000 courses, the announcement said.

Neither treatment would be used in patients before approval by the Medicines and Healthcare products Regulatory Agency (MHRA); trials for PF-07321332/ritonavir are still under way. The supply of molnupiravir is expected to arrive no earlier than mid-November, with the Pfizer antivirals expected in late January.

Ministers and health advisers said the deals, made by the government’s antivirals taskforce, could play a significant role in reducing the extent of serious Covid cases over the winter. The health secretary, Sajid Javid, said they would form part of “an armoury of lifesaving measures to tackle the virus”.

Prof Jonathan Van-Tam, England’s deputy chief medical officer, said antivirals would be “particularly vital in protecting those who may not get the same antibody response to the vaccines as the majority of the population”. He added: “We will now work quickly to ensure the right cohorts of people receive these treatments as soon as possible, should they be approved by the MHRA.”

Health officials expect that most of the antivirals will be used to treat elderly people and immunocompromised individuals, who are most likely to be hospitalised with severe disease. The drugs work in different ways and could be used in combination in the future. The supplies are expected to last this winter and next.

Antivirals, which can be used to either treat those infected with a virus or protect people from becoming infected, have become an increasingly important part of the response to Covid. The health department says the first treatment used for Covid, dexamethasone – a steroid that dampens lung inflammation rather than an antiviral – has since saved 22,000 lives in the UK and about a million worldwide.

One key aim for the taskforce has been to find an antiviral pill that people can take at home before winter sets in.

Most viewed

Most viewed